Subscribe To
TLSA / Top Penny Stocks Today: Why PT, TLSA, AGRI and HTCR Are Up Thursday
TLSA News
By Proactive Investors
October 18, 2023
Tiziana Life Sciences: FDA signs off on home-based protocol fo MS treatment
Regulators have granted approval for home-based self-administration of Intranasal Foralumab, a treatment developed by Tiziana Life Sciences Ltd (NASD more_horizontal
By Proactive Investors
October 16, 2023
Tiziana Life Sciences stock continues to climb; COO ‘excited' by recent results
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares rose 8% to $0.86 in midday trading on Monday after the clinical-stage biopharmaceutical company reveale more_horizontal
By Proactive Investors
October 16, 2023
Tiziana Life Sciences reveals positive clinical results for MS patients treated with Foralumab
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced six-month data showing positive clinical improvements related to Modified Fatigue Impact Scale ( more_horizontal
By Proactive Investors
October 16, 2023
Tiziana Life Sciences' Matthew Davis discusses significance of latest MS treatment data
In an exclusive interview with Thomas Warner from Proactive, Matthew Davis, the chief medical officer and chief operating officer of Tiziana Life Scie more_horizontal
By Proactive Investors
October 13, 2023
Tiziana Life Sciences reveals positive PET scan results with Foralumab to treat MS patients
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that a reduction in activated microglia, as seen in six-month Positron Emission Tomography (PET) s more_horizontal
By Proactive Investors
October 11, 2023
Tiziana Life Sciences to present MS treatment at ECTRIMS Annual Congress
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that a late breaking poster titled, "Treatment Of Six Non-Active Secondary Progressive MS With N more_horizontal
By Proactive Investors
September 26, 2023
Tiziana Life Sciences initiates multi-center Phase 2a clinical trial of intranasal foralumab for na-SPMS
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it has commenced site initiation for its lead intranasal foralumab program entering Phase 2a clinical te more_horizontal
By Proactive Investors
September 6, 2023
Tiziana Life Sciences highlights publication of promising intranasal foralumab in Alzheimer's study results
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said a study validating the mechanism of action of its drug candidate intranasal foralumab in Alzheimer's Dise more_horizontal